SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
The New England Journal of Medicine Publishes Results From Astellas Pharma Inc. and Medivation, Inc.'s Phase 3 AFFIRM Trial of Enzalutamide